工作經歷：

1. 2016.6－ 福州大學生物科學與工程學院

2. 2010.6－2011.6 哈佛大學醫學院（訪問學者）

3. 2003.7－2016.6 中國科學院福建物質結構研究所

教育經歷：

4. 2005.3－2008.7 中國科學院福建物質結構研究所生物化學與分子生物學 博士

5. 2000.9－2003.7 福建師范大學生物化學與分子生物學 碩士

教學簡介：

本科生課程《蛋白質化學與工程》，研究生課程《蛋白質結構與現代藥物開發》。指導學生獲得福建省研究生優秀學位論文。

科研簡介：

主要從事蛋白的結構和功能研究，并基于結構進行多肽和蛋白類藥物的改造和評價。目前已發表SCI論文九十余篇，先后主持國家自然科學基金面上項目及福建省自然科學基金重點項目等。主要研究領域包括：

1、腫瘤遷移相關蛋白的結構和功能研究：幾乎90％癌癥病人的死亡是由于癌細胞的轉移性擴散引起。目前針對原發性腫瘤的治療卓有成效，但靶向腫瘤轉移方面的進展卻不盡人意。我們主要針對腫瘤遷移相關的一些蛋白如尿激酶受體系統和多種絲氨酸蛋白酶，及其與抑制劑的復合物進行X-射線晶體結構研究，并針對這些結構指導抑制劑的改造，以發展高效特異的腫瘤治療藥物。

2、血栓形成相關蛋白的結構和功能研究：人體保持血液處于正常流動狀態，主要依賴于凝血系統和纖溶系統處于一個動態平衡。病理條件下兩個系統的功能異常將導致出血或血栓形成。我們針對凝血和纖溶相關的一些蛋白如纖溶酶原激活物tPA、多種凝血因子及它們的調控蛋白PDI進行結構和功能的研究，并基于這些結構進行抑制劑的設計和改造，以發展高效且無出血副作用的溶栓和抗血栓形成藥物。

3、光動力抗腫瘤和抗菌研究：光敏劑在特定波長的光激發下可產生具有生物毒性的單線態氧或者自由基，進而殺死細胞或微生物，可用于抗腫瘤和抗菌方面的治療。傳統的光敏劑存在靶向性差，水溶性不佳等問題。我們對光敏劑進行一系列的修飾和包裹，發展高靶向性光敏劑，用于抗腫瘤和耐藥菌的治療。

主持的科研項目：

6. 福建省自然科學基金重點項目，基于結構的溶栓劑改造及聯合用藥策略優化（2022J02017），2022.08-2025.08

7. 國家自然科學基金面上項目，內吞性膠原蛋白受體Endo180的結構研究（31570745），2016.01-2019.12

8. 國家自然科學基金面上項目，肝細胞生長因子激活物抑制劑1的結構研究（31170707），2012.1-2015.12

9. 國家自然科學基金面上項目，基質降解相關蛋白的結構研究（30770429），2008.1-2010.12

近五年代表性論文：（*為通訊作者）

10. Li HL, Qu YH, Guo ZZ, Chen D, Jiang LG, Xu P, Huang MD*, Yuan C*. Dual modified ferritin nanocages for tumor-targeted and microenvironment-responsive drug delivery. International Journal of Biological Macromolecules 2025, 303.

11. Zhang DP, Du LY, Gao HS, Yuan C*, Lin ZH*. Structural insight into the Csx1-Crn2 fusion self-limiting ribonuclease of type III CRISPR system. Nucleic Acids Research 2024, 52(14), 8419-8430.

12. Yan W, Li HL, Ning JM, Huang SH, Jiang LG, Xu P, Huang MD*, Yuan C*. Engineered protein cages with enhanced extracellular drug release for elevated antitumor efficacy. International Journal of Biological Macromolecules 2024, 267.

13. Xu YY, Hu YP, Wu GQ, Niu LL, Fang C, Li YK, Jiang LG, Yuan C*, Huang MD*. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment. International Journal of Biological Macromolecules 2024, 257.

14. Wang GD, Li JH, Zhang W, Jiang LB, Mai YH, Chen JY, Deng LA, Chen LY, Lin YX, Li XM, Zou HS, Xu P, Jiang LG, Yuan C*, Huang MD*. A class of photosensitizer highly effective to control bacterial infection in plants even on rainy days with dim light. Dyes and Pigments 2024, 225.

15. Li JH, Wang GD, Mai YH, Zhang W, Zhao HL, Zhou Y, Chen LY, Lin YX, Jiang LG, Xu P, Zhou XL*, Yuan C*, Huang MD*. Lysosome-localization and tumor-targeting of novel photosensitizers enhance the ablation of cancer. Journal of Photochemistry and Photobiology B-Biology 2024, 261.

16. Chen SL, Fang SD, Zhou Y, Huang ZW, Yu SJ, Chen D, Wang ZY, Xu YY, Liu PW, Li YK, Lin W, Jiang LG, Yuan C*, Huang MD*. A low bleeding risk thrombolytic agent: citPA5. Cardiovascular Research 2024, 120(10), 1191-1201.

17. Xu YY, Chen D, Liu PW, Hu YP, Peng SZ, Chen SL, Li YK, Lin W, Jiang LG, Yuan C*, Huang MD*. A triple fusion tissue-type plasminogen activator (TriF-AtPA) enhanced thrombolysis in carotid embolism-induced stroke model. International Journal of Pharmaceutics 2023, 637.

18. Liu DF, Jiang LG, Chen JC, Chen Z, Yuan C*, Lin DH*, Huang MD*. Monomer and Oligomer Transition of Zinc Phthalocyanine Is Key for Photobleaching in Photodynamic Therapy. Molecules 2023, 28(12).

19. Liao XY, Ji PP, Chi KX, Chen XY, Zhou Y, Chen SL, Cheng Y, Flaumenhaft R, Yuan C*, Huang MD*. Enhanced inhibition of protein disulfide isomerase and anti-thrombotic activity of a rutin derivative: rutin:Zn complex. Rsc Advances 2023, 13(17), 11464-11471.

20. Li HL, Wang ZY, Yu SJ, Chen SL, Zhou Y, Qu YH, Xu P, Jiang LG, Yuan C*, Huang MD*. Albumin-based drug carrier targeting urokinase receptor for cancer therapy. International Journal of Pharmaceutics 2023, 634.

21. Yu SJ, Sui YQ, Wang JW, Li YD, Li HL, Cao YP, Chen LQ, Jiang LG, Yuan C*, Huang MD*. Crystal structure and cellular functions of uPAR dimer. Nature Communications 2022, 13(1).

22. Wang GD, Yang L, Jiang LB, Chen JY, Jing Q, Mai YH, Deng LA, Lin YX, Chen LY, Chen Z, Xu P, Jiang LG, Yuan C*, Huang MD*. A new class of quaternary ammonium compounds as potent and environmental friendly disinfectants. Journal of Cleaner Production 2022, 379.

23. Liao XY, Zhuang XX, Liang CH, Li JY, Flaumenhaft R, Yuan C*, Huang MD*. Flavonoids as Protein Disulfide Isomerase Inhibitors: Key Molecular and Structural Features for the Interaction. Journal of Agricultural and Food Chemistry 2022, 70(14), 4475-4483.

24. Liang CH, Flaumenhaft R, Yuan C*, Huang MD*. Vascular thiol isomerases: Structures, regulatory mechanisms, and inhibitor development. Drug Discovery Today 2022, 27(2), 626-635.

25. Liang CH, Cai MQ, Xu YY, Fu W, Wu JH, Liu YR, Liao XY, Ning JM, Li JY*, Huang MD*, Yuan C*. Identification of Antithrombotic Natural Products Targeting the Major Substrate Binding Pocket of Protein Disulfide Isomerase. Journal of Natural Products 2022, 85(5), 1332-1339.

26. Huang ZW, Lin HJ, Yu SJ, Li HL, Zhou Y, Cheng Y, Chen SL, Yuan C*, Huang MD*. A versatile insertion point on albumin to accommodate peptides and maintain their activities. International Journal of Biological Macromolecules 2022, 205, 49-54.

27. Chen SL#, Yuan C#, Jiang LG, Luo ZP*, Huang MD*. Crystallographic analysis of interaction between cisplatin and human serum albumin: Effect of fatty acid. International Journal of Biological Macromolecules 2022, 216, 172-178.

28. Chen SL, Chen D, Liu YR, Xu YY, Lin HJ, Cheng Y, Li JY, Meng C, Liang ML, Yuan C*, Huang MD*. Enhanced clot lysis by a single point mutation in a reteplase variant. British Journal of Haematology 2022, 196(4), 1076-1085.

29. Chen D, Liu YR, Liu PW, Zhou Y, Jiang LG, Yuan C*, Huang MD*. Orally delivered rutin in lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibition. Drug Delivery 2022, 29(1), 1824-1835.

30. Zhang D, Chen JY, Jing Q, Chen Z, Ullah A, Jiang LG, Zheng K, Yuan C*, Huang MD*. Development of a Potent Antimicrobial Peptide With Photodynamic Activity. Frontiers in Microbiology 2021, 12.

31. Yuan C, Guo ZZ, Yu SJ, Jiang LG*, Huang MD*. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discovery Today 2021, 26(4), 1076-1085.

32. Yu SJ, Sun GH, Sui YQ, Li HL, Mai YH, Wang GD, Zhang N, Bi YH, Gao GF, Xu P, Jiang LG, Yuan C*, Yang Y*, Huang MD*. Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds. Dyes and Pigments 2021, 194.

33. Li LL, Huang MX, Shen JS, Wang Y, Wang R, Yuan C*, Jiang LG, Huang MD. Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity. Journal of Infectious Diseases 2021, 223(1), 178-179.

34. Jiang LG, Yuan C*, Huang MD*. A general strategy to inhibit serine protease by targeting its autolysis loop. Faseb Journal 2021, 35(2).

35. Jiang LB, Jiang YB, Li LL, Zheng K, Yu SJ, Li JY, Yuan C*, Huang MD*. A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase. Journal of Controlled Release 2021, 334, 153-163.

36. 許燕艷; 陳珊莉; 陳丹; 彭雙周; 程媛; 李金宇; 李永坤; 江龍光; 袁彩*; 黃明東*. 缺血性腦卒中溶栓藥物研究進展. 生物工程學報 2020, 36 (10), 2029-2039.

37. 梁程輝; 陳丹; 廖馨源; 江龍光; 袁彩*; 黃明東*. 蛋白質二硫鍵異構酶的結構及抑制劑研究進展. 生物化學與生物物理進展 2020, 47 (07), 595-606.

38. Li LL, Chen D, Zheng K, Jiang LB, Dai T, Yang L, Jiang LG, Chen Z, Yuan C*, Huang MD*. Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel. Acs Applied Materials & Interfaces 2020, 12(4), 4221-4230.

39. Jiang YB, Lin L*, Chen SL, Jiang LG, Kriegbaum MC, Grdsvoll H, Hansen LV, Li JY, Ploug M, Yuan C*, Huang MD*. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain. International Journal of Biological Sciences 2020, 16(6), 981-993.

40. Jiang LB, Liu YR, Xu XY, Su D, Zou HS, Liu JY, Yuan C*, Huang MD*. Inhibition of the Citrus Canker Pathogen Using a Photosensitizer Assisted by Sunlight Irradiation. Frontiers in Microbiology 2020, 11.

其他

研究生招生專業：生物醫學工程、生物工程、生物技術與工程；歡迎有志從事科研工作的碩士生報考我們課題組。

課題組介紹：http://fmerc.fzu.edu.cn/html/rcdw/hmdktz/1.html